University of Aberdeen spin-out company Auvation – which is developing innovative technologies for the diagnosis and treatment of cancer – has joined forces with an Irish cancer specialist.
Cork based healthcare company EiRx Therapeutics plc has acquired a controlling shareholding in Auvation, which is based at the Aberdeen Science and Technology Park. EiRx is also negotiating to buy the remaining shareholder interests.
Dr William Melvin, Chief Executive Officer and founder of Auvation, said: “I am delighted that Auvation and EiRx are joining forces in the fight against cancer. Whilst both companies pursue the development of new cancer therapeutics, the capabilities they have independently assembled are highly complementary.”